Printer Friendly

BRISTOL-MYERS SQUIBB'S CAPOTEN REINSTATED ON MEDI-CAL FORMULARY

 PRINCETON, N.J., Nov. 4 /PRNewswire/ -- Bristol-Myers Squibb (NYSE: BMY) has announced that Capoten(R) (captopril), the company's established drug for the treatment of heart failure and high blood pressure, has been reinstated on the Medi-Cal formulary, effective Dec. 1.
 Medi-Cal administers the U.S. Medicaid program to more than 4.5 million California members.
 Importantly, Medi-Cal prescribers will no longer need to request prior approval, nor inquire about Continuing Care Therapy for Capoten after Dec. 1, 1993. Therefore, Capoten will be available for Medi-Cal recipients without restriction.
 This reinstatement comes less than two months after Capoten was cleared by the Food and Drug Administration for expanded use following a myocardial infarction (MI) or heart attack. Specifically, Capoten is the only angiotensin converting enzyme (ACE) inhibitor indicated to improve survival and clinical outcomes (reduce hospitalization for and the development of heart failure) in post-MI patients with left ventricular dysfunction (ejection fraction less than or equal to 40 percent). In this setting, Capoten can be initiated as early as three days following a heart attack.
 Bristol-Myers Squibb is a research-based, diversified health care company whose principal businesses are pharmaceuticals, consumer products, nutritionals, and medical devices. It is among the world's leading makers of cardiovascular, anticancer, anti-infective, central nervous system and dermatological drug therapies, diagnostic agents and non-prescription medicines.
 /delval/
 -0- 11/4/93
 /CONTACT: Robert F. Laverty of Bristol-Myers Squibb, 609-252-5551/
 (BMY)


CO: Bristol Myers Squibb ST: New Jersey IN: MTC SU:

MP -- PH012 -- 0684 11/04/93 11:40 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 4, 1993
Words:250
Previous Article:CAMPBELL, NAKANO FORM JOINT VENTURE TO MARKET SOUP IN JAPAN
Next Article:PGA HIRES COUNSEL
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters